Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Erlotinib

3

XV.f Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

1
Last update : 22/04/2013
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Tyrosine kinase inhibitors (EGFR) TKI
5

Publications

[Fatal interstitial lung disease associated with erlotinib use].
Nederlands tijdschrift voor geneeskunde 2013;157;A5519 2013
Erlotinib-associated near-fatal interstitial pneumonitis in a patient with relapsed lung adenocarcinoma.
Chang Gung medical journal 2010;33;100-5 2010
Fatal interstitial lung disease after erlotinib for non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008 Sep;3;1050-3 2008 Sep
Pulmonary toxicity associated with erlotinib.
Chest 2007 Sep;132;1042-4 2007 Sep
Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2007 Dec;26;1340-4 2007 Dec
Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.
BMC cancer 2007 Aug 05;7;150 2007 Aug 05

Powered by

  • ^
  • Contact
  • Cookies
  • About